Kanak Raina, Chris D Forbes, Rebecca Stronk, Jonathan P Rappi, Kyle J Eastman, Samuel W Gerritz, Xinheng Yu, Hao Li, Amit Bhardwaj, Mia Forgione, Abigail Hundt, Madeline P King, Zoe M Posner, Allison Denny, Andrew McGovern, David E Puleo, Ethan Garvin, Rebekka Chenard, Nilesh Zaware, James J Mousseau, Jennifer Macaluso, Michael Martin, Kyle Bassoli, Kelli Jones, Marco Garcia, Katia Howard, Levi M Smith, Jinshan M Chen, Cesar A De Leon, John Hines, Katherine J Kayser-Bricker, Craig M Crews
While specific cell signaling pathway inhibitors have yielded great success in oncology, directly triggering cancer cell death is one of the great drug discovery challenges facing biomedical research in the era of precision oncology. Attempts to eradicate cancer cells expressing unique target proteins, such as antibody-drug conjugates (ADCs), T-cell engaging therapies, and radiopharmaceuticals have been successful in the clinic, but they are limited by the number of targets given the inability to target intracellular proteins...
January 2, 2023: bioRxiv